{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:F7VJQ1",
      "entity_text" : "PRP",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:482576",
      "entity_text" : "tamarixetin",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "This is supported by the observation that tamarixetin inhibits significantly platelet aggregation in PRP at concentrations of 10 muM and higher, with quercetin and isorhamnetin inhibiting significantly at> = 25 muM (the higher concentrations required here may be explained by stirring conditions and use of collagen [5 mug/mL] as agonist; XREF_SUPPLEMENTARY).",
  "reading_complete" : "2020-08-03T15:00:20Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T14:57:21Z",
  "trigger" : "inhibits",
  "evidence" : [ "tamarixetin inhibits significantly platelet aggregation in PRP" ],
  "pmc_id" : "6667742",
  "score" : 0
}